Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 2011 AL 2025

Comparison of virtual reality versus physical reality on movement characteristics of persons with Parkinson's disease: effects of moving targets

Wang CY, Hwang WJ, Fang JJ, Sheu CF, Leong IF, Ma HI.

Arch Phys Med Rehabil. 2011 Aug;92(8):1238-45. doi: 10.1016/j.apmr.2011.03.014. Epub 2011 Jun 30.

Three spinocerebellar ataxia type 2 siblings with ataxia, parkinsonism, and motor neuronopathy

Nishikawa N, Nagai M, Tsujii T, Tanabe N, Takashima H, Nomoto M.

Intern Med. 2011;50(13):1429-32. doi: 10.2169/internalmedicine.50.5262. Epub 2011 Jul 1.

Neuropathology underlying clinical variability in patients with synucleinopathies

Halliday GM, Holton JL, Revesz T, Dickson DW.

Acta Neuropathol. 2011 Aug;122(2):187-204. doi: 10.1007/s00401-011-0852-9. Epub 2011 Jul 1.

The A53T mutation is key in defining the differences in the aggregation kinetics of human and mouse α-synuclein

Kang L, Wu KP, Vendruscolo M, Baum J.

J Am Chem Soc. 2011 Aug 31;133(34):13465-70. doi: 10.1021/ja203979j. Epub 2011 Aug 8.

Can α-synuclein be targeted in novel therapies for Parkinson's disease?

Brundin P, Olsson R.

Expert Rev Neurother. 2011 Jul;11(7):917-9. doi: 10.1586/ern.11.73.

Pramipexole for the treatment of early Parkinson's disease

Perez-Lloret S, Rey MV, Ratti L, Rascol O.

Expert Rev Neurother. 2011 Jul;11(7):925-35. doi: 10.1586/ern.11.75.

Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates

Torres EM, Lane EL, Heuer A, Smith GA, Murphy E, Dunnett SB.

J Neurosci Methods. 2011 Aug 30;200(1):29-35. doi: 10.1016/j.jneumeth.2011.06.012. Epub 2011 Jun 23.

Sexual problems in Parkinson's disease: the multidimensional nature of the problem and of the intervention

Bronner G.

J Neurol Sci. 2011 Nov 15;310(1-2):139-43. doi: 10.1016/j.jns.2011.05.050. Epub 2011 Jul 1.

Exploring the link between glucocerebrosidase mutations and parkinsonism

Westbroek W, Gustafson AM, Sidransky E.

Trends Mol Med. 2011 Sep;17(9):485-93. doi: 10.1016/j.molmed.2011.05.003. Epub 2011 Jul 1.

L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?

Lipski J, Nistico R, Berretta N, Guatteo E, Bernardi G, Mercuri NB.

Prog Neurobiol. 2011 Sep 1;94(4):389-407. doi: 10.1016/j.pneurobio.2011.06.005. Epub 2011 Jun 24.

Intensive voice treatment (LSVT®LOUD) for Parkinson's disease following deep brain stimulation of the subthalamic nucleus

Spielman J, Mahler L, Halpern A, Gilley P, Klepitskaya O, Ramig L.

J Commun Disord. 2011 Nov-Dec;44(6):688-700. doi: 10.1016/j.jcomdis.2011.05.003. Epub 2011 Jun 13.

The pathophysiological mechanisms underlying freezing of gait in Parkinson's Disease

Shine JM, Naismith SL, Lewis SJ.

J Clin Neurosci. 2011 Sep;18(9):1154-7. doi: 10.1016/j.jocn.2011.02.007. Epub 2011 Jul 2.

Stochastic resonance therapy in Parkinson's disease

Kaut O, Allert N, Coch C, Paus S, Grzeska A, Minnerop M, Wüllner U.

NeuroRehabilitation. 2011;28(4):353-8. doi: 10.3233/NRE-2011-0663.

Impulse control disorders in Parkinson's disease: recent advances

Voon V, Mehta AR, Hallett M.

Curr Opin Neurol. 2011 Aug;24(4):324-30. doi: 10.1097/WCO.0b013e3283489687.

c-Abl in neurodegenerative disease

Schlatterer SD, Acker CM, Davies P.

J Mol Neurosci. 2011 Nov;45(3):445-52. doi: 10.1007/s12031-011-9588-1. Epub 2011 Jul 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias